Business & Regulation Standards & Regulation, Quality & Compliance

Five Steps You Won’t Want to Miss When Filing an IND

Set yourself up for success by asking these questions along the IND application process.

09/20/2019

sponsored by Regis

The FDA requires drug makers to submit an Investigational New Drug (IND) application when shipping an unapproved product across state lines for human clinical trials, as well as for approved products being studied for not-yet-approved uses. For a New Chemical Entity, filing an IND is the first step towards a first-in-human Phase I clinical trial. Active Pharmaceutical Ingredients targeting a new therapeutic indication require an IND filing as well.

What are the most important things to consider when filing an IND? This infographic, sponsored by Regis, sets out the five key steps to success.

Click Here to Download

Email*

Choose a password

I have read and understand the Privacy Notice *

Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

I want to stay up to date with the "Small Molecule" field I want to stay up to date with the Cell and Gene field I want to stay up to date with the Bioprocessing field

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.